Neurocrine Biosciences, Inc. (NBIX)
| Market Cap | 14.67B +2.7% |
| Revenue (ttm) | 3.37B +34.4% |
| Net Income | 705.50M +102.6% |
| EPS | 6.82 +101.2% |
| Shares Out | 101.65M |
| PE Ratio | 21.16 |
| Forward PE | 12.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 514,497 |
| Open | 144.56 |
| Previous Close | 146.00 |
| Day's Range | 143.00 - 145.95 |
| 52-Week Range | 122.14 - 186.12 |
| Beta | 0.40 |
| Analysts | Strong Buy |
| Price Target | 206.22 (+42.85%) |
| Earnings Date | Nov 2, 2026 |
About NBIX
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical develo... [Read more]
Financial Performance
In 2025, Neurocrine Biosciences's revenue was $2.86 billion, an increase of 21.45% compared to the previous year's $2.36 billion. Earnings were $478.60 million, an increase of 40.23%.
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for NBIX stock is "Strong Buy." The 12-month stock price target is $206.22, which is an increase of 42.85% from the latest price.
News
Neurocrine presents new analysis establishing benchmark in dyskinesia treatment
Neurocrine (NBIX) announced new research that helps define clinically meaningful improvement in overall health reported by people living with tardive dyskinesia who were treated with Ingrezza – albena...
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings in patients with tardive dyskinesia treated with I...
Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome
Expert perspectives highlight the interaction of hypothalamic dysfunction, biological, behavioral, and environmental factors in shaping the challenges of hyperphagia in Prader-Willi syndrome for patie...
Neurocrine begins Phase 2 study of NBI-‘567 in adults with Alzheimer’s disease
Neurocrine (NBIX) announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 in adults with mild to moderate Alzheimer’s disease. NBI-‘567 is designed to directly a...
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in ...
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia
Decades of real-world medical records highlight the diverse challenges of living with classic congenital adrenal hyperplasia and how needs evolve from childhood through adulthood Patient records showe...
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
Conference Call and Webcast Scheduled for Monday, November 2 SAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarte...
Neurocrine price target lowered to $150 from $164 at BMO Capital
BMO Capital lowered the firm’s price target on Neurocrine (NBIX) to $150 from $164 and keeps a Market Perform rating on the shares as part of a broader research note…
Neurocrine assumed with a Buy at Guggenheim
Guggenheim analyst Delma Caiati assumed coverage of Neurocrine (NBIX) with a Buy rating and $207 price target Neurocrine has transitioned from a single-product story into “a diversified neuropsychiatr...
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
PWS-VISTA observational study will build longitudinal real-world evidence on VYKAT XR use for hyperphagia in Prader-Willi syndrome in routine clinical practice BRAVE-PWS observational study will captu...
Neurocrine price target lowered to $214 from $231 at UBS
UBS lowered the firm’s price target on Neurocrine (NBIX) to $214 from $231 and keeps a Buy rating on the shares. The 25% pullback since Q2 reflects concerns around Vykat…
Neurocrine names Eiry Roberts, M.D., as Chief Medical Officer
Neurocrine (NBIX) Biosciences announced that Eiry Roberts, M.D., who previously served as Neurocrine’s Chief Medical Officer and currently serves as a Strategic Advisor, will rejoin the company’s exec...
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D.
SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Eiry W.
Neurocrine Biosciences Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
China-originated innovation and AI are reshaping R&D and operational strategies, while Medicare policy changes will impact pricing and revenue for key products. Growth is driven by strong commercial performance in CRENESSITY and VYKAT XR, with a robust pipeline targeting new indications and therapeutic areas.
Neurocrine price target raised to $183 from $182 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Neurocrine (NBIX) to $183 from $182 and keeps an Equal Weight rating on the shares. The firm identifies NBIP-2118 in obesity as…
Neurocrine Biosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Expanded from a single to multi-product portfolio, achieving strong sales and pipeline growth. INGREZZA drives robust performance with significant market potential, while CRENESSITY and VYKAT XR show early commercial success. IRA-related pricing impacts are managed, and late-stage pipeline assets are poised to fuel future growth.
Neurocrine Biosciences Transcript: Wells Fargo 21st Annual Healthcare Conference
Ingrezza continues to grow, with 2027 volume expected to offset pricing pressure. CRENESSITY adoption and persistence support continued growth, while VYKAT XR integration targets sequential sales growth; multiple Phase III readouts are expected in 2027-2028.
Neurocrine price target raised to $253 from $249 at Citi
Citi raised the firm’s price target on Neurocrine (NBIX) to $253 from $249 and keeps a Buy rating on the shares. Citi’s endocrinologist survey supports continued growth for Crenessity, the…
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: Wells Fargo 21 st Annua...
Neurocrine announces INECT-PRO Phase 4 open-label study results
Neurocrine (NBIX) Biosciences announced publication of the KINECT-PRO Phase 4 open-label study results demonstrating that treatment with once-daily INGREZZA, or valbenazine, capsules resulted in subst...
Neurocrine price target lowered to $165 from $190 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Neurocrine (NBIX) to $165 from $190 and keeps a Hold rating on the shares. The firm believes the Vykat commercial launch is…
Neurocrine price target lowered to $182 from $196 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Neurocrine (NBIX) to $182 from $196 and keeps an Equal Weight rating on the shares.
Neurocrine price target lowered to $218 from $221 at Bernstein
Bernstein lowered the firm’s price target on Neurocrine (NBIX) to $218 from $221 and keeps an Outperform rating on the shares. The firm notes Neurocrine reported promising Q2 earnings. Bernstein…
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia acros...
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug
Experts in Prader-Willi Syndrome on Tuesday raised safety concerns over Neurocrine's drug Vykat XR, citing serious adverse events reported in patients with the rare genetic disorder.